{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:58:55Z","timestamp":1793177935316,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancer treatment-related adverse events (AEs) are sometimes associated with outcomes for cancer patients, especially with the newest therapies such as target therapy and immunotherapy. A few years ago, the first-line therapy for hormone-receptor-positive metastatic breast cancer (mBC) patients has been deeply changed by the introduction of cyclin-dependent kinase (CDK) 4\/6 inhibitors, and now, we are improving our knowledge about their AEs and significance in clinical practice. Here, we report our experience with two cases of vitiligo-like lesions that occur early during treatment with ribociclib. We tried to change the CDK4\/6 inhibitor for one patient, but the skin reaction persisted. Both patients retained only the endocrine therapy alone and had an unexpected durable progression-free survival (PFS). Some data on skin toxicities, including vitiligo-like lesions by CDK4\/6 inhibitors, have recently been reported in the literature, but for the first time, we highlight a possible correlation with improved survival outcomes of patients. Uncovering the etiology of this toxicity, verifying the involvement of the immune system, and demonstrating a possible positive impact in survival represent an intriguing research objective for the near future.<\/jats:p>","DOI":"10.3389\/fonc.2023.1067264","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T06:36:51Z","timestamp":1678343811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response"],"prefix":"10.3389","volume":"13","author":[{"given":"Mariangela","family":"Pasqualoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Garufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Cannizzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Pontolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Pannunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cutigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Sollena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709","article-title":"\u00abRibociclib as first-line therapy for HR-positive, advanced breast cancer\u00bb","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu444","article-title":"Association between treatment toxicity and outcomes in oncology clinical trials","volume":"25","author":"Abola","year":"2014","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres","article-title":"Immune-related adverse effects and outcome of patients with cancer treated with immune checkpoint inhibitors","volume":"40","author":"Fiala","year":"2020","journal-title":"Anticancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3068","article-title":"Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis","volume":"31","author":"Fontein","year":"2013","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225731","article-title":"Melanoma and vitiligo: In good company","volume":"20","author":"Failla","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00645-0","article-title":"Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: Signals from disproportionality analysis of the FDA adverse event reporting system","volume":"23","author":"Raschi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-6-6","article-title":"Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: Results from an observational, cross-sectional study","volume":"9","author":"Suh Oh","year":"2020","journal-title":"Drugs Context."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.10.006","article-title":"Immunotherapy \u201cShock\u201d with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma","volume":"26","author":"Zarogoulidis","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","article-title":"Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis","volume":"77","author":"Dai","year":"2017","journal-title":"J Am Acad Dermatol;"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1915279","article-title":"Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion","volume":"20","author":"Lommerts","year":"2021","journal-title":"Expert Opin Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12413.x","article-title":"Cytotoxic T lymphocyte reactivity to gp100, MelanA\/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients","volume":"121","author":"Mandelcorn-Monson","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05914-w","article-title":"European Network for cutaneous ADverse event of oncologic drugs (ENCADO) group. vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors","volume":"185","author":"Sollena","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-3299-2","article-title":"Lineage infidelity of MDA-MB-435 cells: Expression of melanocyte proteins in a breast cancer cell line","volume":"64","author":"Sellappan","year":"2004","journal-title":"Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1067264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T06:36:55Z","timestamp":1678343815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1067264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":18,"alternative-id":["10.3389\/fonc.2023.1067264"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1067264","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"article-number":"1067264"}}